The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | J | Antiinfectives for systemic use | |
| 2 | J05 | Antivirals for systemic use | |
| 3 | J05A | Direct acting antivirals | |
| 4 | J05AR | Antivirals for treatment of HIV infections, combinations | |
| 5 | J05AR02 | Lamivudine and abacavir |
| Active Ingredient | Description | |
|---|---|---|
| Lamivudine and Abacavir |
Abacavir and lamivudine are NRTIs, and are potent selective inhibitors of HIV-1 and HIV-2 (LAV2 and EHO) replication. Both abacavir and lamivudine are metabolised sequentially by intracellular kinases to the respective 5'-triphosphate (TP) which are the active moieties. Their main antiviral activity is through incorporation of the monophosphate form into the viral DNA chain, resulting in chain termination. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| KIVEXA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
